Company / Cash & Equivalents
Autonomix Medical, Inc. Cash & Equivalents History
FY2024-FY2026 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$7.0M
FY2026
5-year range
$7.0M / $9.1M
FY2024-FY2026
Trend
-23.3%
vs FY2025
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from $9M to $7M over the past 2 years.
Based on SEC 10-K filings.
$7M in FY2026.
Declined from $9M to $7M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2026, cash & equivalents decreased 23.3% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 0/9 (multiple financial health concerns)
- Altman Z-Score -5.47 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2026 | $7.0M | -23.3% |
| FY2025 | $9.1M | +6.1% |
| FY2024 | $8.6M | - |
As of FY2026 · SEC 10-K · Updated Jun 24, 2026